Strong survival benefit for AstraZeneca's Casodex

6 February 2006

Anglo-Swedish drug major AstraZeneca says that new data demonstrate that the addition of 150mg Casodex (bicalutamide) to radiotherapy reduces the risk of death by 35% in men with locally-advanced prostate cancer compared to radiotherapy alone (p = 0.03).

According to the firm, the findings, published in the February edition of the British Journal of Urology, provide the first evidence of an overall survival benefit for treating locally-advanced prostate cancer with adjuvant hormonal therapy, which is not based on castration.

These data are important as up to 43% of men with locally-advanced disease who receive treatment with radiotherapy alone, traditionally the treatment of choice, die within five years of therapy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight